A Study of LY3007113 in Participants With Advanced Cancer
NCT01463631
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
27
Enrollment
INDUSTRY
Sponsor class
Conditions
Metastatic Cancer
Interventions
DRUG:
LY3007113
Sponsor
Eli Lilly and Company